id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-D-1794-0010,FDA,FDA-2020-D-1794,"Evaluation of Gastric pH-Dependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis,
and Clinical Implications; Guidance for Industry; Availability",Notice,Notice of Availability,2023-03-13T04:00:00Z,2023,3,,,2023-03-13T15:38:33Z,2023-05067,0,0,090000648579b62f
FDA-2020-D-1794-0011,FDA,FDA-2020-D-1794,"Evaluation of Gastric pH-Dependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications; Guidance for Industry; Final Guidance",Other,Guidance,2023-03-13T04:00:00Z,2023,3,2023-03-13T04:00:00Z,,2024-11-07T00:48:56Z,,1,0,090000648579c248
FDA-2020-D-1794-0001,FDA,FDA-2020-D-1794,"Evaluation of Gastric pH-Dependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications; Draft Guidance for Industry; Availability",Notice,Notice of Availability,2020-12-01T05:00:00Z,2020,12,2020-12-01T05:00:00Z,2021-03-02T04:59:59Z,2021-03-02T02:00:56Z,2020-26510,0,0,090000648497f79e
FDA-2020-D-1794-0002,FDA,FDA-2020-D-1794,"Evaluation of Gastric pH-Dependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications Guidance for Industry",Other,Guidance,2020-12-01T05:00:00Z,2020,12,2020-12-01T05:00:00Z,,2020-12-01T16:55:53Z,,0,0,090000648497fc38